Profile of certolizumab and its potential in the treatment of psoriatic arthritis

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 339-348

  Chimenti, Maria Sole ^a   Saraceno, Rosita ^a   Chiricozzi, Andrea ^a,b   Giunta, Alessandro ^a   Chimenti, Sergio ^a   Perricone, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Anti TNF; Biological therapies; Certolizumab pegol; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

CAUSAL ATTRIBUTION; CELL MEDIATED CYTOTOXICITY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNE RESPONSE; INFECTION; INNATE IMMUNITY; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; PSORIASIS; PSYCHOLOGY; RADIOGRAPHY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; POLYETHYLENE GLYCOLS; PSORIASIS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876227774     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S31658     Document Type: Review

References (59)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314-320.
2. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460-1468.
3. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24(3):518-523.
4. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs. 2000;9(7):1511-1522.
5. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001;60(4):316-321.
6. Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49(4):697-705.
7. Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev. 2007;6(8):524-528.
8. Strohal R, Chimenti S, Vena GA, Girolomoni G. Etanercept provides an effective, safe and flexible short-and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. J Dermatolog Treat. Epub November 10, 2012.
9. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007;56(8):2698-2707.
10. Papoutsaki M, Costanzo A, Chimenti MS, Chimenti S. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opin Biol Ther. 2008;8(3):363-370.
11. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-279.
12. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9): 1387-1394.
13. FitzGerald O, McInnes I. Spondyloarthropathy: disease at the crossroads of immunity. Best Pract Res Clin Rheumatol. 2006;20(5):949-967.
14. Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Aut Rev 2013 Mar;12(5):599-606.
15. Hueber AJ, McInnes IB. Immune regulation in psoriasis and psoriatic arthritis-recent developments. Immunol Lett. 2007;114(2):59-65.
16. Codullo V, McInnes IB. Synovial tissue response to treatment in psoriatic arthritis. Open Rheumatol J. 2011;5:133-137.
17. Gerhard N, Krenn V, Magalhães R, Morawietz L, Brändlein S, König A. IgVH-genes analysis from psoriatic arthritis shows involvement of antigen-activated synovial B-lymphocytes. Z Rheumatol. 2002;61(6):718-727.
18. Cañete JD, Santiago B, Cantaert T, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis. 2007;66(6):720-726.
19. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev. 2007;7(1):35-41.
20. Baeten D, Kruithof E, Van den Bosch F, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. 2001;44(1):186-195.
21. Ohshima S, Mima T, Sasai M, et al. Tumour necrosis factor alpha (TNF-a) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF therapy for RA. Cytokine. 2000;12(3):281-288.
22. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis. 2005;64(4): 529-536.
23. Chimenti MS, Perricone C, Graceffa D, et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30(1):23-30.
24. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1): 4-12.
25. Statkute L, Ruderman EM. Novel TNF antagonists for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2010;19(1):105-115.
26. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford). 2002;41(10):1133-1137.
27. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2001;40(7):539-551.
28. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor agents. Inflamm Bowel Dis. 2007;13(11):1323-1332.
29. Cominelli F. Cytokine-based therapies for Crohn's disease-new paradigms. N Engl J Med. 2004;351(20):2045-2048.
30. Ueda N, Tsukamoto H, Mitoma H, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Ann Rheum Dis. 2012;71 Suppl 3:665.
31. Ohshima S, Saeki Y, Mima T, et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol. 1999;19(5):305-313.
32. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 2010;10(3): 308-315.
33. Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signalling of membrane integrated TNF in monocytes. Cytokine. 2004;28(2):67-74.
34. Watts AD, Hunt NH, Wanigasekara Y, et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling.' EMBO J. 1999;18(8):2119-2126.
35. Harashima S, Horiuchi T, Hatta N, et al. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol. 2001;166(1):130-136.
36. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[alpha]. Gastroenterology. 2005;128(2):376-392.
37. Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004;15(5): 353-366.
38. van Lent PL, Blom AB, Grevers L, Sloetjes A, van den Berg WB. Toll-like receptor 4induced FcgR expression potentiates early onset of joint inflammation and cartilage destruction during immune complex arthritis: Toll-like receptor 4 largely regulates FcgR expression by IL-10. Ann Rheum Dis. 2007;66(3):334-340.
39. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129(3):807-818. Erratum in: Gastroenterology. 2005;129(5):1808.
40. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled phase III study (PRECiSE 1). Gastroenterology. 2006;130 Suppl 2: A1-A912.
41. Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35(4):757-773.
42. Colombel J, Sandborn WJ, Rutgeerts P, et al. Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: results of the CHARM trial. Gastroenterology. 2006;130 Suppl 2:A1-A912.
43. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21(3):251-258.
44. Jazayeri JA, Carroll GJ. Fc-based cytokines: prospects for engineering superior therapeutics. Bio Drugs. 2008;22(1):11-26.
45. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348(1-2):36-41.
46. Fleischmann R. The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. Expert Opin Biol Ther. 2010;10(5):773-786.
47. Mease PJ, Fleischmann RM, Deodhar A et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2012;71(Suppl3):LB0001.
48. Sieper J, Kivitz AJ, Van Tubergen AM, et al. Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study. Ann Rheum Disease. 2012;64(Suppl10):558.
49. Deeks ED. Certolizumab Pegol: A Review of Its Use in the Management of Rheumatoid Arthritis. Drugs. 2013;22. [Epub ahead of print]
50. Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010;69 Suppl 1:i2-29. Erratum in: Ann Rheum Dis. 2011;70(8):1519.
51. Furst DE, Shaikh SA, Greenwald M, et al. Evaluation of two dosing regimens of certolizumab pegol for maintenace of clinical response in patients with active rheumatoid arthritis: primary results from Doseflex, a Phase IIIB study. Ann Rheum Dis. 2012; 71(Suppl3):SAT0126.
52. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4 WARD study. Ann Rheum Dis. 2009;68(6):805-811.
53. Ramiro S, van Tubergen AM, Landewé RB. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6(5):713-720.
54. Van der Heijde D, Maksymowych W, Landewé R, et al. Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12 week magnetic resonance imaging results of a phase 3 double blind randomized placebo-controlled study. Arthritis Rheum. 2012; 64(Suppl10):1705
55. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondyloarthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68 Suppl 2:ii1-ii44.
56. Reich k, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the pegylated fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180-190.
57. Shu Q, Amin MA, Ruth JH, et al. Suppression of endothelial cell activity by inhibition of TNFα. Arthritis Res Ther. 2012;14(2):R88.
58. Mease PJ, Fleischmann RM, Wollenhaupt J, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis with and without prior anti-TNF exposure: 24 week results of a phase 3 double-blind randomized placebo-controlled study. Ann Rheum Dis. 2012;71 Suppl 3:150.
59. Gladman DD, Fleischmann RM, Coteur G, Woltering F, Mease P. Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients: 24 week patient reported outcome results of a phase 3 double blind randomized placebo-controlled study. Arthritis Rheum. 2012;64 Suppl 10:557.